Russian-made pharmpreparation semaglutide in the experience of de-intensification of diabetes mellitus treatment: A clinical case

The actual concept of type 2 diabetes mellitus (T2DM) treatment includes optimizing the management of metabolic health, primarily glycemia and body weight, as well as preventing the development of cardiovascular diseases (CVD), chronic kidney disease (CKD), and metabolically associated fatty liver disease (MAFLD). Reduction of fat mass contributes to stable compensation of carbohydrate and lipid metabolism, control of blood pressure and reduction of cardiovascular risk, CKD and MAFLD. Glucagonlike peptide-1 (GLP-1Ap) receptor agonists are a highly effective class of drugs for the treatment of patients with T2DM, both by increasing the effectiveness and safety of glycemic control, and by having additional positive effects on the cardiovascular system and body weight. Studies have revealed numerous positive pleiotropic effects of semaglutide, which allows for better management of type 2 diabetes. For the first time in 2019 The Russian clinical guidelines and Algorithms for specialized medical care for patients with diabetes mellitus included information on the proven priority treatment of T2DM with CVD of atherosclerotic origin with GLP-1Ar class drugs. The development of a domestically reproduced drug, Semavik®, has made it possible to increase the availability of semaglutide preparations in the Russian Federation and expand the possibilities of pathogenetically based therapy providing cardiometabolic and other pleiotropic benefits in patients with T2DM. This clinical example presents the results of the efficacy and safety of the Russian semaglutide Semavik® in a patient suffering from long–term uncompensated T2DM, morbid obesity and receiving insulin therapy. Against the background of the addition of domestic GLP-1Ar to therapy, significant positive dynamics of glycemia and other metabolic parameters, weight loss, and improvement in objective examination indicators were achieved. The appointment of a domestic semaglutide made it possible to de-intensify insulin therapy in the form of its cancellation. The use of domestic semaglutide shows and proves its effectiveness not only in achieving the target values of blood glucose levels, but also in reducing body weight and normalizing the lipid profile.

1. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Kutakova DV, Mokrysheva NG. Epidemiology and key clinical and therapeutic indicators of diabetes mellitus in Russian Federation according to the World Health Organization’s strategy goals. Diabetes Mellitus. 2025;28(1):4–17. (In Russ.) https://doi.org/10.14341/DM13292.

2. Sztanek F, Tóth LI, Pető A, Hernyák M, Diószegi Á, Harangi M. New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists. Biomedicines. 2024;12(6):1320. https://doi.org/10.3390/biomedicines12061320.

3. Zanozina OV, Sorokina YuA, Kalugina YeV, Zhuk SD, Plastova NN, Taradayko NYu et al. Russian-Made Pharmpreparation Semaglutide in True Clinical Practice. Effective Pharmacotherapy. 2024;20(52):6–12. (In Russ.) Available at: https://umedp.ru/articles/opyt_primeneniya_rossiyskogo_preparata_semaglutida_v_realnoy_klinicheskoy_praktike.html.

4. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394–405. https://doi.org/10.1016/S0140-6736(21)01919-X.

5. Romantsova TI. Innovative approaches to the treatment of obesity: from pharmacotherapy to nanomedicine. Obesity and Metabolism. 2024;21(4):389–404. (In Russ.) https://doi.org/10.14341/omet13184.

6. Kanavets NS, Rebrova DV. Clinical cases of management of patients with type 2 diabetes mellitus using GLP-1 receptor agonists. Farmateka. 2024;(8):124–132. (In Russ.) https://doi.org/10.18565/pharmateca.2024.8.124-132.

7. Noskov SM, Arefeva AN, Banko VV, Radaeva КS, Gefen ML, Archakova OA et al. Semaglutide for the treatment of obesity: Results of two open randomized pharmacokinetic studies. Meditsinskiy Sovet. 2024;(16):216–222. (In Russ.) https://doi.org/10.21518/ms2024-346.

8. Demidova TYu, Ushanova FO, Bogacheva TL. Semaglutide in type 2 diabetes management: review of current evidence from concept to date. FOCUS. Endocrinology. 2023;4(3):13–28. (In Russ.) https://doi.org/10.15829/2713-0177-2023-3-11.

9. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–536. https://doi.org/10.1111/dom.12849.

10. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al. Diabetes Technology: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S111–S127. https://doi.org/10.2337/dc23-S007.

11. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20–S42. https://doi.org/10.2337/dc24-S002.

12. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. https://doi.org/10.1093/eurheartj/ehad192.

13. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102. https://doi.org/10.1016/j.molmet.2020.101102.

14. Levit S, Torban N, Boaz M, Weichman M, Azuri J, Manisterski Y et al. Gravicentric approach to Type 2 Diabetes therapy. The success prediction. A proof-of-concept. Pharmacy Formulas. 2020;2(2):48–60. https://doi.org/10.17816/phf34728.

15. Van Dril E, Allison M, Schumacher C. Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. Am Heart J Plus. 2022;17:100163. https://doi.org/10.1016/j.ahjo.2022.100163.

16. Champion M, Wills Avila G, Garcia AE, Álvarez Delgado FM, Valdez CA. Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on DeEscalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team. J Prim Care Community Health. 2024;15:21501319241231398. https://doi.org/10.1177/21501319241231398.

17. Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Netw Open. 2024;7(7):e2421305. https://doi.org/10.1001/jamanetworkopen.2024.21305.